Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA.
Head Neck. 2009 Nov;31(11):1431-8. doi: 10.1002/hed.21111.
Treatment of base of tongue (BOT) squamous cell carcinoma (SCC) has traditionally been associated with poor prognosis and significant morbidity. We report a program consisting of concurrent chemoradiation followed by brachytherapy for these patients.
We reviewed all patients in our institution with previously untreated BOT SCC (1996-2004) who received this treatment program.
In 88 patients (median age, 60.2 years; 37 T1/T2; 51 T3/T4), cervical lymph node metastases were present in 71 patients (80.7%). Six patients had residual/subsequent cervical metastases requiring 7 neck dissections. Local recurrence occurred in 16 patients (18.2%) and distant metastases occurred in 9 patients (10.2%). Median follow-up time was 3.1 years (range, 0.5-7.8 years). Three-year overall survival was 80.9% (95% CI: 69.6% to 88.3%). Locoregional control rate was 79.9% and disease-specific survival was 69.5% at 3 years.
Concurrent chemoradiotherapy followed with brachytherapy is a safe and effective method of treatment of SCC of the BOT.
舌根（BOT）鳞状细胞癌（SCC）的治疗传统上与预后不良和显著发病率相关。我们报告了一个针对这些患者的联合放化疗后近距离放疗方案。
我们回顾了在我们机构中接受这种治疗方案的未经治疗的 BOT SCC 患者（1996-2004 年）。
在 88 例患者中（中位年龄为 60.2 岁；37 例 T1/T2；51 例 T3/T4），71 例患者（80.7%）存在颈部淋巴结转移。6 例患者有残留/后续颈部转移，需要 7 次颈部清扫术。16 例患者出现局部复发（18.2%），9 例患者发生远处转移（10.2%）。中位随访时间为 3.1 年（范围：0.5-7.8 年）。3 年总生存率为 80.9%（95%CI：69.6%至 88.3%）。3 年局部区域控制率为 79.9%，疾病特异性生存率为 69.5%。
联合放化疗后近距离放疗是治疗 BOT SCC 的一种安全有效的方法。
